Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Nov 5 1:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Roof who wrote (830)	4/12/1998 5:44:00 PM
From: Stephen How	of 1432

I finally reviewed the medical literature on coagulopathy of hydroxyethyl starch (HES) plasma expanders. I found the material very readable and relevant to the controversy of Hextend's improved coagulation properties over hetastarch. The issue of HES coagulation has been researched for over 30 years. Several good tutorial review papers were published in the last few years. Although the issue remains unresolved, the consensus seems to be that the high weight hetastarch molecules (MW = 480 kD) interferes with clotting factors, especially for repeated administrations. The trend seems to be the use of lower MW HES solutions as pentastarch (280 kD) in Canada, and 200 kD HES in Europe. It seems the US is behind the trend in it's continued use of hetastarch (480 kD). I've written a summary of what I learned at btim.dyn.ml.org Again, I'm skeptical that any simple addition of Ca solves this long and actively studied, not-completely-understood mechanism. Anecdotally, I found a study that administered 5 l of hetastarch to 4 trauma patients in 1983. Steve

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next